行情

FOMX

FOMX

Foamix
NASDAQ

实时行情|Nasdaq Last Sale

4.700
+0.020
+0.43%
盘后: 4.700 0 0.00% 16:00 01/17 EST
开盘
4.780
昨收
4.680
最高
4.780
最低
4.581
成交量
43.65万
成交额
--
52周最高
4.840
52周最低
1.970
市值
2.89亿
市盈率(TTM)
-3.6182
分时
5日
1月
3月
1年
5年

分析师评级

5位分析师的综合评级

买入

免责声明:分析师观点仅供投资者决策参考,不构成任何买卖投资建议。

EPS

FOMX 新闻

  • Lululemon:谜题待解
  • 界面.1小时前
  • 复飞之路再现波折 波音737Max软件又曝新缺陷
  • 中国新闻网.2小时前
  • 特朗普公布弹劾案辩护团队 参议院审理流程一览
  • 中国新闻网.3小时前
  • 美参院启动弹劾案 特朗普新聘三位律师
  • 央视.3小时前

更多

所属板块

生物技术和医学研究
-0.10%
制药与医学研究
+0.07%

热门股票

名称
价格
涨跌幅

FOMX 简况

Foamix Pharmaceuticals Ltd. is a clinical-stage pharmaceutical company. The Company is engaged in the development and commercialization of foam-based formulations, using its technology, which includes its foam platforms. It is focused on developing and commercializing its minocycline foam for the treatment of acne, rosacea and other skin conditions. Its product candidates include FMX101, FMX102, FMX103 and FDX104. Its lead product candidate, FMX101, is a topical foam formulation of the antibiotic minocycline for the treatment of moderate-to-severe acne. FMX102 is a formulation of its minocycline foam being developed for the treatment of impetigo. FMX103 is a topical foam formulation of minocycline for the treatment of moderate-to-severe Papulopustular rosacea. FDX104 is a topical foam formulation of the antibiotic doxycycline for the treatment of severe acne-like rashes induced by chemotherapy. It has conducted one Phase II clinical trial for each of FMX101, FMX102, FMX103 and FDX104.
展开

Webull提供Foamix Pharmaceuticals Ltd的股票价格,实时市场报价,专业分析师评级,深度图表和免费的股票新闻,以帮助您做出投资决策。